Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial to evaluate adjuvant tislelizumab in high-risk stage I non-small cell lung cancer. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Lung Cancer (NSCLC) | Phase 2 | Status: RECRUITING